Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00 2022-10-06 pm EDT
47.15 USD   -0.65%
10/06RBC Cuts Price Target on Intra-Cellular Therapies to $67 From $70, Maintains Outperform Rating
MT
09/26Insider Sell: Intra-Cellular Therapies
MT
08/22Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Advance Auto Parts...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Intra-Cellular Therapies Q2 Net Loss Widens, Revenue Climbs

08/09/2022 | 07:58am EDT


© MT Newswires 2022
All news about INTRA-CELLULAR THERAPIES, INC.
10/06RBC Cuts Price Target on Intra-Cellular Therapies to $67 From $70, Maintains Outperform..
MT
09/26Insider Sell: Intra-Cellular Therapies
MT
08/22Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Ad..
MS
08/22Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 Fr..
MT
08/15Insider Sell: Intra-Cellular Therapies
MT
08/11Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps..
MT
08/10Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Ratin..
MT
08/10Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains ..
MT
08/09Intra Cellular Therapies : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORP..
PU
08/09Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2..
CI
More news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
More recommendations
Financials (USD)
Sales 2022 235 M - -
Net income 2022 -305 M - -
Net cash 2022 285 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Capitalization 4 451 M 4 451 M -
EV / Sales 2022 17,7x
EV / Sales 2023 9,95x
Nbr of Employees 512
Free-Float 97,5%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 47,15 $
Average target price 68,92 $
Spread / Average Target 46,2%
EPS Revisions
Managers and Directors
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
INTRA-CELLULAR THERAPIES, INC.-9.92%4 451
REGENERON PHARMACEUTICALS, INC.15.89%78 242
VERTEX PHARMACEUTICALS35.99%76 586
BIONTECH SE-46.65%33 422
WUXI APPTEC CO., LTD.-39.54%29 123
GENMAB A/S5.32%23 876